AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 179 filers reported holding AXSOME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $373,982 | -5.8% | 5,351 | -3.2% | 0.00% | – |
| Q2 2023 | $397,170 | +19.4% | 5,527 | +2.5% | 0.00% | – |
| Q1 2023 | $332,578 | -21.5% | 5,392 | -1.9% | 0.00% | – |
| Q4 2022 | $423,829 | +69.5% | 5,495 | -1.9% | 0.00% | – |
| Q3 2022 | $250,000 | -69.3% | 5,600 | -73.7% | 0.00% | -100.0% |
| Q2 2022 | $815,000 | -7.3% | 21,287 | +0.2% | 0.00% | 0.0% |
| Q1 2022 | $879,000 | +9.6% | 21,252 | -0.0% | 0.00% | 0.0% |
| Q4 2021 | $802,000 | +14.1% | 21,253 | -0.2% | 0.00% | 0.0% |
| Q3 2021 | $703,000 | -51.0% | 21,295 | +0.2% | 0.00% | 0.0% |
| Q2 2021 | $1,435,000 | +19.5% | 21,260 | +0.2% | 0.00% | 0.0% |
| Q1 2021 | $1,201,000 | -28.9% | 21,228 | +2.4% | 0.00% | -50.0% |
| Q4 2020 | $1,689,000 | +14.3% | 20,733 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,478,000 | -13.3% | 20,733 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,705,000 | +2839.7% | 20,733 | +1973.3% | 0.00% | – |
| Q1 2020 | $58,000 | -44.2% | 1,000 | 0.0% | 0.00% | – |
| Q4 2019 | $104,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |